Tovorafenib has recently received approval for treatment of pediatric low-grade gliomas driven by KIAA1549:BRAF, a constitutively dimerized form of BRAF created by its truncation and fusion with a portion of the KIAA1549 ORF (33, 34, 35). Here, BRAF is linked to central nervous system cancer.